J&J Exec Says As Part Of 2-year Restructuring Program In MedTech Unit, Expect To Exit Certain Markets And Product Lines; Costs For Restructuring Program In MedTech Unit Estimated To Be Between $700M-$800M
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson (JNJ) has announced a 2-year restructuring program in its MedTech unit, which will involve exiting certain markets and product lines. The estimated costs for this restructuring program are between $700M-$800M.
October 17, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
J&J's restructuring program in its MedTech unit may lead to short-term costs but could potentially streamline operations and improve profitability in the long run.
The restructuring program announced by J&J is a significant move that could have both short-term and long-term impacts on the company. In the short term, the costs associated with the restructuring could potentially impact the company's financial performance. However, in the long term, the restructuring could potentially streamline operations and improve profitability, which could have a positive impact on the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100